Eikon Therapeutics, Inc. (EIKN)
Nasdaq: EIKN · Biological Products, (No Diagnostic Substances) · filing with the SEC since 2021
Income statement, as filed
In thousands of US dollars (USD), as filed; per-share figures in US dollars; share counts. The fiscal year ends in December.The Form 10-K filed Mar 30, 2026 for the period ended Dec 31, 2025 is not in EDGAR's company facts yet; its figures print once EDGAR carries them.
| Fiscal quarter | Q3 FY26 | Q2 FY26 | Q1 FY26 |
|---|---|---|---|
| Period ending | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 |
| Report filed | Nov 12, 2026 | Aug 13, 2026 | May 11, 2026 |
| For lenders | |||
| Net interest income | 4,486 | 5,037 | 4,380 |
| Research and development | 71,826 | 75,460 | 70,047 |
| General and administrative | 18,726 | 17,934 | 17,290 |
| Total operating expenses | 90,552 | 93,394 | 87,337 |
| Operating income | -90,552 | -93,394 | -87,337 |
| Net income including non-controlling interests | · | · | -82,958 |
| Net income | -86,112 | -88,409 | -82,958 |
| Net income to common shareholders | -86,112 | -88,409 | -82,958 |
| Earnings per share, basic | -1.59 | -1.63 | -2.46 |
| Earnings per share, diluted | -1.59 | -1.63 | -2.46 |
| Weighted average shares, basic | 54,168,268 | 54,143,162 | 33,700,550 |
| Weighted average shares, diluted | 54,168,268 | 54,143,162 | 33,700,550 |
As filed with the SEC, each figure from the newest report that carries it, and linked to it. Nothing here is computed.Each quarter is three months. A fourth quarter prints only where the company tagged its three months on their own; the whole year is in the annual view.A dot is a line not tagged for that period. r restated by the company in a later report; b a share figure put on the newest basis or filed in the wrong unit. Hover a figure for its filing and note.
What each line is, and the XBRL concept behind it
Net interest income interest earned less interest paid
us-gaap:InterestIncomeExpenseNetResearch and development spent on inventing what it sells next
us-gaap:ResearchAndDevelopmentExpenseGeneral and administrative the cost of running the company itself
us-gaap:GeneralAndAdministrativeExpenseTotal operating expenses the running costs together
us-gaap:OperatingExpensesOperating income profit from running the business, before interest and tax
us-gaap:OperatingIncomeLossNet income including non-controlling interests the whole group's profit, minority holders' share included
us-gaap:ProfitLossNet income the profit or loss that belongs to the company's shareholders
us-gaap:NetIncomeLossNet income to common shareholders what is left for common shareholders
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasicEarnings per share, basic net income per share outstanding
us-gaap:EarningsPerShareBasicEarnings per share, diluted net income per share, counting every share that could be issued
us-gaap:EarningsPerShareDilutedWeighted average shares, basic the average count of shares outstanding
us-gaap:WeightedAverageNumberOfSharesOutstandingBasicWeighted average shares, diluted the average count with every share that could be issued
us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding